HLS Therapeutics Comments on Rule Enacted by Quebec Health Minister Christian Dubé and the Absence of an Exception for New Refractory Schizophrenic Patients

About this update from Hls Therapeutics, Inc.

[{"type":"text","content":"\n \n \n \n HLS Therapeutics Comments on Rule Enacted by Quebec Health Minister Christian Dubé and the Absence of an Exception for New Refractory Schizophrenic Patients\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n DORVAL, QC\n \n ,\n \n April 1, 2021\n \n /CNW Telbec/ - HLS Therapeutics Inc. regrets the adoption of a new regulation, published yesterday in the Gazette officielle du Québec, which limits access to a support program for new patients suffering from refractory schizophrenia, and urgently requests a meeting with the\n \n Quebec\n \n Minister of Health and Social Services Christian Dubé.\n \n \n This regulation will impact access of new patients to the risk management program called CSAN (CLOZARIL® Support and Assistance Network), a care portal and patient registry required by Health Canada for patients prescribed CLOZARIL® (clozapine), a treatment of last resort prescribed by psychiatrists to treat patients with refractory schizophrenia who do not respond to other treatments.\n \n \n For nearly five years, HLS has enabled new patients to have access to CSAN and to CLOZARIL by covering the difference in cost between its medication and the amount reimbursed by RAMQ. By removing the cost difference, physicians were able to choose the support system best suited to the needs of their patients, without any financial impact.\n \n \n The published regulation was meant to define the exceptions to the application of Article 80.2 of Law 92, which prohibits the reimbursement of all, or part of a drug covered by the\n \n Quebec\n \n general drug insurance plan. However,\n \n although patients currently on treatment will continue to be able to benefit from access to CSAN/CLOZARIL®\n \n , the government has chosen not to allow for an exception for future patients. Thus, deprived of financial assistance from CSAN, new patients will not have access to CSAN unless they pay the difference between the price of CLOZARIL® and the cost reimbursed by the RAMQ, a near impossible requirement given the oft...

More updates from Hls Therapeutics, Inc.